Pharmaceutical compositions of 5,7,14-triazatetracyclo [10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene

Disclosed is a controlled release dosage form suitable for administration to a subject comprising 5,8,14-triazatetra-cyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene, and a means for administering the compound to the subject at a rate of less than about 6 mg/hour, whereby the controlled rele...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: ROY, MICHAEL CHRISTOPHER, SMITH, SCOTT WENDELL, QUAN, ERNEST SHING, MOSES, SARA KRISTEN, WATERMAN, KENNETH CRAIG, AM ENDE, MARY TANYA
Format: Patent
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator ROY, MICHAEL CHRISTOPHER
SMITH, SCOTT WENDELL
QUAN, ERNEST SHING
MOSES, SARA KRISTEN
WATERMAN, KENNETH CRAIG
AM ENDE, MARY TANYA
description Disclosed is a controlled release dosage form suitable for administration to a subject comprising 5,8,14-triazatetra-cyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene, and a means for administering the compound to the subject at a rate of less than about 6 mg/hour, whereby the controlled release dosage form is formulated such that at least about 0.1 mg of the compound is administered over a 24 hour period. Also disclosed is a controlled release dosage form formulated such that, when dosed to a subject the dosage form results in a time for maximum plasma concentration (Tmax) that is increased for the drug in an initial administration to the subject by an average of 50% of the corresponding Tmax determined for an equal does of the pentaene in the form of an immediate release bolus. Also disclosed is a controlled release dosage form formulated such that the dosage releases the pentaene at a rate of less than 6 mgA/hr in vitro when dissolution tested in a USP-2 apparatus, such that the time for dissolution of 50 w/w% of the drug is between 1 and 15 hours.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_NZ532435A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>NZ532435A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_NZ532435A3</originalsourceid><addsrcrecordid>eNqFjrEKwjAURbs4iPoLkrGFpDRNi3QUUZzEwUkp5RFfaaBNQvME9eut4O504HIunHk0nDsYB9D4IKOhZ9oN3gVDxtnAXMtKvuGyEDQaeAMhjaBfunfsJrNUpTLN4pxLmUwseJXUosMn3FGDyONpVvz7r4RHS4AWl9GshT7g6sdFtD7sL7ujQO8aDH7qsEjN6VqqvFDlVv0VPt5KOl0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Pharmaceutical compositions of 5,7,14-triazatetracyclo [10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene</title><source>esp@cenet</source><creator>ROY, MICHAEL CHRISTOPHER ; SMITH, SCOTT WENDELL ; QUAN, ERNEST SHING ; MOSES, SARA KRISTEN ; WATERMAN, KENNETH CRAIG ; AM ENDE, MARY TANYA</creator><creatorcontrib>ROY, MICHAEL CHRISTOPHER ; SMITH, SCOTT WENDELL ; QUAN, ERNEST SHING ; MOSES, SARA KRISTEN ; WATERMAN, KENNETH CRAIG ; AM ENDE, MARY TANYA</creatorcontrib><description>Disclosed is a controlled release dosage form suitable for administration to a subject comprising 5,8,14-triazatetra-cyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene, and a means for administering the compound to the subject at a rate of less than about 6 mg/hour, whereby the controlled release dosage form is formulated such that at least about 0.1 mg of the compound is administered over a 24 hour period. Also disclosed is a controlled release dosage form formulated such that, when dosed to a subject the dosage form results in a time for maximum plasma concentration (Tmax) that is increased for the drug in an initial administration to the subject by an average of 50% of the corresponding Tmax determined for an equal does of the pentaene in the form of an immediate release bolus. Also disclosed is a controlled release dosage form formulated such that the dosage releases the pentaene at a rate of less than 6 mgA/hr in vitro when dissolution tested in a USP-2 apparatus, such that the time for dissolution of 50 w/w% of the drug is between 1 and 15 hours.</description><edition>7</edition><language>eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2005</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20050429&amp;DB=EPODOC&amp;CC=NZ&amp;NR=532435A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76516</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20050429&amp;DB=EPODOC&amp;CC=NZ&amp;NR=532435A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ROY, MICHAEL CHRISTOPHER</creatorcontrib><creatorcontrib>SMITH, SCOTT WENDELL</creatorcontrib><creatorcontrib>QUAN, ERNEST SHING</creatorcontrib><creatorcontrib>MOSES, SARA KRISTEN</creatorcontrib><creatorcontrib>WATERMAN, KENNETH CRAIG</creatorcontrib><creatorcontrib>AM ENDE, MARY TANYA</creatorcontrib><title>Pharmaceutical compositions of 5,7,14-triazatetracyclo [10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene</title><description>Disclosed is a controlled release dosage form suitable for administration to a subject comprising 5,8,14-triazatetra-cyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene, and a means for administering the compound to the subject at a rate of less than about 6 mg/hour, whereby the controlled release dosage form is formulated such that at least about 0.1 mg of the compound is administered over a 24 hour period. Also disclosed is a controlled release dosage form formulated such that, when dosed to a subject the dosage form results in a time for maximum plasma concentration (Tmax) that is increased for the drug in an initial administration to the subject by an average of 50% of the corresponding Tmax determined for an equal does of the pentaene in the form of an immediate release bolus. Also disclosed is a controlled release dosage form formulated such that the dosage releases the pentaene at a rate of less than 6 mgA/hr in vitro when dissolution tested in a USP-2 apparatus, such that the time for dissolution of 50 w/w% of the drug is between 1 and 15 hours.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2005</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqFjrEKwjAURbs4iPoLkrGFpDRNi3QUUZzEwUkp5RFfaaBNQvME9eut4O504HIunHk0nDsYB9D4IKOhZ9oN3gVDxtnAXMtKvuGyEDQaeAMhjaBfunfsJrNUpTLN4pxLmUwseJXUosMn3FGDyONpVvz7r4RHS4AWl9GshT7g6sdFtD7sL7ujQO8aDH7qsEjN6VqqvFDlVv0VPt5KOl0</recordid><startdate>20050429</startdate><enddate>20050429</enddate><creator>ROY, MICHAEL CHRISTOPHER</creator><creator>SMITH, SCOTT WENDELL</creator><creator>QUAN, ERNEST SHING</creator><creator>MOSES, SARA KRISTEN</creator><creator>WATERMAN, KENNETH CRAIG</creator><creator>AM ENDE, MARY TANYA</creator><scope>EVB</scope></search><sort><creationdate>20050429</creationdate><title>Pharmaceutical compositions of 5,7,14-triazatetracyclo [10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene</title><author>ROY, MICHAEL CHRISTOPHER ; SMITH, SCOTT WENDELL ; QUAN, ERNEST SHING ; MOSES, SARA KRISTEN ; WATERMAN, KENNETH CRAIG ; AM ENDE, MARY TANYA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_NZ532435A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2005</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>ROY, MICHAEL CHRISTOPHER</creatorcontrib><creatorcontrib>SMITH, SCOTT WENDELL</creatorcontrib><creatorcontrib>QUAN, ERNEST SHING</creatorcontrib><creatorcontrib>MOSES, SARA KRISTEN</creatorcontrib><creatorcontrib>WATERMAN, KENNETH CRAIG</creatorcontrib><creatorcontrib>AM ENDE, MARY TANYA</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ROY, MICHAEL CHRISTOPHER</au><au>SMITH, SCOTT WENDELL</au><au>QUAN, ERNEST SHING</au><au>MOSES, SARA KRISTEN</au><au>WATERMAN, KENNETH CRAIG</au><au>AM ENDE, MARY TANYA</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Pharmaceutical compositions of 5,7,14-triazatetracyclo [10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene</title><date>2005-04-29</date><risdate>2005</risdate><abstract>Disclosed is a controlled release dosage form suitable for administration to a subject comprising 5,8,14-triazatetra-cyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene, and a means for administering the compound to the subject at a rate of less than about 6 mg/hour, whereby the controlled release dosage form is formulated such that at least about 0.1 mg of the compound is administered over a 24 hour period. Also disclosed is a controlled release dosage form formulated such that, when dosed to a subject the dosage form results in a time for maximum plasma concentration (Tmax) that is increased for the drug in an initial administration to the subject by an average of 50% of the corresponding Tmax determined for an equal does of the pentaene in the form of an immediate release bolus. Also disclosed is a controlled release dosage form formulated such that the dosage releases the pentaene at a rate of less than 6 mgA/hr in vitro when dissolution tested in a USP-2 apparatus, such that the time for dissolution of 50 w/w% of the drug is between 1 and 15 hours.</abstract><edition>7</edition><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_NZ532435A
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title Pharmaceutical compositions of 5,7,14-triazatetracyclo [10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T23%3A57%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ROY,%20MICHAEL%20CHRISTOPHER&rft.date=2005-04-29&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ENZ532435A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true